United States Pneumococcal Vaccines Market Size, Trends & Forecast 2025 | Major Players 2025 - Pfizer Inc., Merck & Co., Serum Institute of India Pvt. Ltd.

"The Global Pneumococcal Vaccines Market reached US$ 7.96 billion in 2023 and is expected to reach US$ 11.9 billion by 2031 growing with a CAGR of 5.2% during the forecast period 2024-2031." As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/pneumococcal-vaccines-market?sp

United States: Recent Pneumococcal Vaccine Developments

✅ In September 2025, Pfizer launched its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) in New York targeting adults and high-risk populations.The vaccine offers broader protection and enhanced immune response compared to previous versions.

✅ In August 2025, Merck & Co. invested $55 million to expand its pneumococcal vaccine R&D and manufacturing facilities in Pennsylvania.The initiative focuses on next-generation conjugate vaccines.Commercial rollout is expected by Q1 2026.

✅ In July 2025, Sanofi Pasteur introduced a novel pneumococcal vaccine booster in Massachusetts with improved long-term immunity and simplified dosing schedule.The vaccine supports adult and pediatric immunization programs.

✅ In June 2025, GSK completed clinical trials for an advanced pneumococcal vaccine in California targeting multiple serotypes.The results demonstrated strong immunogenicity and favorable safety profiles, preparing for FDA submission.

Japan: Recent Pneumococcal Vaccine Developments

✅ In September 2025, Takeda Pharmaceuticals launched a next-generation pneumococcal conjugate vaccine (PCV20) in Tokyo for adults and high-risk groups.The vaccine enhances protection against multiple strains of Streptococcus pneumoniae.

✅ In August 2025, Daiichi Sankyo invested in R&D and production of advanced pneumococcal vaccines in Osaka.The focus is on conjugate and booster formulations.Pilot production is underway with nationwide rollout expected in 2026.

✅ In July 2025, KM Biologics introduced an updated pneumococcal vaccine in Kyoto with improved immunogenicity and long-lasting protection for infants and adults.The initiative supports Japan's national immunization program.

✅ In June 2025, Shionogi & Co. completed clinical validation of a novel pneumococcal vaccine platform in Fukuoka.The platform integrates enhanced adjuvant technology to boost immune response.Nationwide deployment is planned by late 2025.

Pneumococcal Vaccines Market: Drivers

The pneumococcal vaccines market is experiencing significant growth as healthcare providers and governments increasingly focus on preventing pneumococcal infections, which can cause pneumonia, meningitis, and bloodstream infections, particularly in children, the elderly, and immunocompromised individuals. Rising adoption is driven by expanding immunization programs, growing awareness of vaccine-preventable diseases, and the need to reduce morbidity and mortality rates globally. Additionally, increasing investments in public health infrastructure, vaccination campaigns, and global health initiatives are fueling market demand. The rising prevalence of respiratory infections and the push for preventive healthcare further support market growth. Efforts to improve vaccine accessibility in low- and middle-income countries are also contributing to adoption trends.

Technological advancements are significantly enhancing pneumococcal vaccine development and deployment. Innovations in conjugate vaccine technology improve immunogenicity, efficacy, and protection against multiple pneumococcal serotypes. Development of next-generation vaccines, including higher-valent formulations, aims to expand coverage and provide long-term immunity. Advances in cold-chain logistics, scalable manufacturing, and quality control ensure safe distribution and accessibility in diverse regions. Integration of digital monitoring, data tracking, and immunization registries enhances vaccination coverage and compliance. With ongoing innovation and increasing global immunization efforts, the pneumococcal vaccines market is poised for sustained growth.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/pneumococcal-vaccines-market?sp

Pneumococcal Vaccines Market: Major Players

Pfizer Inc., Merck & Co., Inc., Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co., Ltd., SINOVAC, Beijing Minhai Biological Technology Co., Ltd., SK bioscience., Sanofi, Biological E Limited., CanSinoBIO, Panacea Biotec, GSK plc. and Inventprise among others

Segment Covered in the Pneumococcal Vaccines Market:

➥ By Type: Pneumococcal Conjugate Vaccine (PCV), Pneumococcal Polysaccharide Vaccine (PPV), Next Generation Pneumococcal Vaccines

➥ By Route of Administration: Intramuscular, Subcutaneous

➥ By Patient Type: Infants (

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.